REG - Oxford BioDynamics - Publication of 2025 Annual Report

RNS Number : 4871M Oxford BioDynamics PLC 22 December 2025 Oxford BioDynamics Plc("OBD" or the "Company" and, together with its subsidiaries, the "Group")Publication of 2025 Annual ReportOxford, UK - 22 December 2025 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that its annual report and accounts for the year ended 30 September 2025 ("Annual Report") is available in electronic form on its website at www.oxfordbiodynamics.com/investors/financial-results. Hard copies of the report (incorporating the Notice of Annual General Meeting) will be posted to shareholders today.As stated in the preliminary results announcement on 16 December 2025, the Company's Annual General Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK on 26 January 2026 at 11.00 am.-Ends-For further details please contact: Oxford BioDynamics PlcTel: +44 (0) 1865 518910Iain Ross Executive ChairmanPaul Stockdale, CFOShore Capital - Nominated Adviser and BrokerTel: +44 (0) 20 7408 4090Stephane Auton / Lucy BowdenOAK Securities - Joint BrokerTel: +44 (0) 20 3973 3678Matthew Clarke / Tim Dainton / Calvin ManCamarco - Financial PRTel: +44 (0) 20 3757 4980Marc Cohen / Tilly Butcher / Fergus YoungOBDFinancial@camarco.co.ukNotes to EditorsAbout Oxford BioDynamics PlcOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.OBD is listed on the London Stock Exchange's AIM . For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ACSUUORRVKUUUAA